{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:25:06Z","timestamp":1785349506901,"version":"3.55.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002345","name":"Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010127","name":"J\u00fcrgen Manchot Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010127","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.retram.2025.103545","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:22:52Z","timestamp":1759551772000},"page":"103545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Revolutionizing pediatric gene and cell therapy: The hope for lipid-based nanoparticles in blood disorders"],"prefix":"10.1016","volume":"73","author":[{"given":"Fatemeh","family":"Zahedipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh Mohammadian","family":"Gol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silas","family":"Wisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Ure\u00f1a-Bail\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Mezger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2025.103545_bib0001","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-formulations-choice-paediatric-population_en.pdf\/(accessed on 28 November 2020). CfHMPoEMARPFoCftPPAo."},{"key":"10.1016\/j.retram.2025.103545_bib0002","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-revision-1_en.pdf\/(accessed on 28 November 2020). CfHMPoEMAIERGoCIoMPitPPSAo."},{"issue":"11","key":"10.1016\/j.retram.2025.103545_bib0003","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.clinthera.2012.09.013","article-title":"Eunice kennedy shriver national institute of child health and human development pediatrics formulation initiative: proceedings from the second workshop on pediatric formulations","volume":"34","author":"Giacoia","year":"2012","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.retram.2025.103545_bib0004","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of Patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.retram.2025.103545_bib0005","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"10.1016\/j.retram.2025.103545_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/VIW.20200111","article-title":"Nanoparticle-mediated siRNA delivery systems for cancer therapy","volume":"2","author":"Gao","year":"2021","journal-title":"View"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0007","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/leu.2017.269","article-title":"RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo","volume":"32","author":"Jyotsana","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.retram.2025.103545_bib0008","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1021\/acs.molpharmaceut.3c00479","article-title":"The transformative potential of lipid nanoparticle-protein corona for next-generation vaccines and therapeutics","volume":"20","author":"Amici","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.retram.2025.103545_bib0009","series-title":"Lipid nanocarriers for drug targeting","author":"Grumezescu","year":"2018"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-2836(65)80093-6","article-title":"Diffusion of univalent ions across the lamellae of swollen phospholipids","volume":"13","author":"Bangham","year":"1965","journal-title":"J Mol Biol"},{"issue":"3","key":"10.1016\/j.retram.2025.103545_bib0011","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1023\/A:1018965121222","article-title":"Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes","volume":"11","author":"Harashima","year":"1994","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.retram.2025.103545_bib0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jfda.2017.02.001","article-title":"Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers","volume":"25","author":"Lin","year":"2017","journal-title":"J Food Drug Anal"},{"key":"10.1016\/j.retram.2025.103545_bib0013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2017.01.014","article-title":"BCS class IV drugs: Highly notorious candidates for formulation development","volume":"248","author":"Ghadi","year":"2017","journal-title":"J Controlled Release"},{"issue":"30","key":"10.1016\/j.retram.2025.103545_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202006619","article-title":"All-in-one dendrimer-based lipid nanoparticles enable precise HDR-mediated gene editing in vivo","volume":"33","author":"Farbiak","year":"2021","journal-title":"Adv Mater"},{"issue":"6","key":"10.1016\/j.retram.2025.103545_bib0015","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.apsb.2022.04.013","article-title":"Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm Sin B"},{"issue":"17","key":"10.1016\/j.retram.2025.103545_bib0016","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.retram.2025.103545_bib0017","doi-asserted-by":"crossref","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","author":"Mehta","year":"2023","journal-title":"ACS Mater Au"},{"issue":"11","key":"10.1016\/j.retram.2025.103545_bib0018","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: A bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proceed National Acad Sci"},{"issue":"17","key":"10.1016\/j.retram.2025.103545_bib0019","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1038\/emboj.2011.286","article-title":"Endosome maturation","volume":"30","author":"Huotari","year":"2011","journal-title":"EMBO J"},{"issue":"5646","key":"10.1016\/j.retram.2025.103545_bib0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/271672a0","article-title":"Effects of fusogenic agent on membrane structure of erythrocyte ghosts and the mechanism of membrane fusion","volume":"271","author":"Cullis","year":"1978","journal-title":"Nature"},{"issue":"1-2","key":"10.1016\/j.retram.2025.103545_bib0021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2533\/chimia.1997.34","article-title":"The proton sponge: a trick to enter cells the viruses did not exploit","volume":"51","author":"Behr","year":"1997","journal-title":"Chimia (Aarau)"},{"issue":"7","key":"10.1016\/j.retram.2025.103545_bib0022","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"9","key":"10.1016\/j.retram.2025.103545_bib0023","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1021\/acs.nanolett.7b02664","article-title":"Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA","volume":"17","author":"Patel","year":"2017","journal-title":"Nano Lett"},{"issue":"6","key":"10.1016\/j.retram.2025.103545_bib0024","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater Au"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijpharm.2017.08.064","article-title":"Nanoprecipitation process: from encapsulation to drug delivery","volume":"532","author":"Mart\u00ednez Rivas","year":"2017","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0026","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1038\/s41467-020-15889-3","article-title":"Size and surface charge characterization of nanoparticles with a salt gradient","volume":"11","author":"Rasmussen","year":"2020","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.retram.2025.103545_bib0027","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1007\/s00216-017-0527-z","article-title":"Zeta potential: a case study of cationic, anionic, and neutral liposomes","volume":"409","author":"Smith","year":"2017","journal-title":"Anal Bioanal Chem"},{"issue":"9","key":"10.1016\/j.retram.2025.103545_bib0028","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1021\/acs.langmuir.2c02794","article-title":"Morphological behavior of liposomes and lipid nanoparticles","volume":"39","author":"Zhigaltsev","year":"2023","journal-title":"Langmuir"},{"issue":"36","key":"10.1016\/j.retram.2025.103545_bib0029","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angewandte Chemie (International ed in English)"},{"key":"10.1016\/j.retram.2025.103545_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1753-2000-2-37","article-title":"Regulation (EC) No 1901\/2006 on medicinal products for paediatric use & clinical research in vulnerable populations","volume":"2","author":"Lehmann","year":"2008","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"10.1016\/j.retram.2025.103545_bib0031","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1053\/j.semperi.2015.08.006","article-title":"Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?","volume":"39","author":"Ren","year":"2015","journal-title":"Semin Perinatol"},{"issue":"3","key":"10.1016\/j.retram.2025.103545_bib0032","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/2168479017696265","article-title":"Pediatric medicine development: an overview and comparison of regulatory processes in the European Union and United States","volume":"51","author":"Penkov","year":"2017","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.retram.2025.103545_bib0033","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.addr.2019.08.008","article-title":"Pharmacokinetics of nanotechnology-based formulations in pediatric populations","volume":"151-152","author":"Yellepeddi","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.retram.2025.103545_bib0034","doi-asserted-by":"crossref","unstructured":"Nieto Gonz\u00e1lez N, Obinu A, Rassu G, Giunchedi P, Gavini E. Polymeric and Lipid Nanoparticles: Which Applications in Pediatrics? Pharmaceutics 2021, 13, 670. s Note: MDPI stays neutral with regard to jurisdictional claims in published \u2026; 2021.","DOI":"10.3390\/pharmaceutics13050670"},{"key":"10.1016\/j.retram.2025.103545_bib0035","unstructured":"CDER, Center for Drug Evaluation and Research (CDER), center for biologics evaluation and research (CBER), Food and Drug Administration Guidance for Industry: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products, 2014."},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0036","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","article-title":"Factors and mechanisms for pharmacokinetic differences between pediatric population and adults","volume":"3","author":"Fernandez","year":"2011","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0037","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/17425247.4.1.37","article-title":"Paediatric and geriatric drug delivery","volume":"4","author":"Breitkreutz","year":"2007","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"10.1016\/j.retram.2025.103545_bib0038","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1517\/17425255.1.3.447","article-title":"Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations","volume":"1","author":"Strolin Benedetti","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.retram.2025.103545_bib0039","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"10.1016\/j.retram.2025.103545_bib0040","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3390\/pharmaceutics13101681","article-title":"Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for t (8; 21) pediatric acute myeloid leukemia","volume":"13","author":"Connerty","year":"2021","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.retram.2025.103545_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061603","article-title":"Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles","volume":"15","author":"Swart","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.retram.2025.103545_bib0042","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1039\/C6RA25493D","article-title":"In vivo protein corona patterns of lipid nanoparticles","volume":"7","author":"Amici","year":"2017","journal-title":"RSC Adv"},{"issue":"4","key":"10.1016\/j.retram.2025.103545_bib0043","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.apsb.2020.10.023","article-title":"Impact of particle size and pH on protein corona formation of solid lipid nanoparticles: A proof-of-concept study","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"12","key":"10.1016\/j.retram.2025.103545_bib0044","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"New England J Med"},{"issue":"2","key":"10.1016\/j.retram.2025.103545_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017213","article-title":"Age-related differences in plasma proteins: how plasma proteins change from neonates to adults","volume":"6","author":"Ignjatovic","year":"2011","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.retram.2025.103545_bib0046","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1039\/C8NR09855G","article-title":"The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles","volume":"11","author":"Chen","year":"2019","journal-title":"Nanoscale"},{"issue":"5","key":"10.1016\/j.retram.2025.103545_bib0047","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jpeds.2012.07.016","article-title":"Improving drug formulations for neonates: making a big difference in our smallest patients","volume":"161","author":"Noel","year":"2012","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-4165(85)90174-6","article-title":"Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection","volume":"839","author":"Senior","year":"1985","journal-title":"Biochimica et biophysica acta (BBA)-general subjects"},{"issue":"2","key":"10.1016\/j.retram.2025.103545_bib0049","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0005-2736(91)90201-I","article-title":"Pharmacokinetics of stealth versus conventional liposomes: effect of dose","volume":"1068","author":"Allen","year":"1991","journal-title":"Biochimica et Biophysica Acta (BBA)-Biomembranes"},{"issue":"2","key":"10.1016\/j.retram.2025.103545_bib0050","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01477-16","article-title":"Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1821","key":"10.1016\/j.retram.2025.103545_bib0051","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"Simon","year":"2015","journal-title":"Proceed Royal Society B: Biol Sci"},{"issue":"12","key":"10.1016\/j.retram.2025.103545_bib0052","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/s41409-019-0510-8","article-title":"CRISPR\/Cas9-modified hematopoietic stem cells-present and future perspectives for stem cell transplantation","volume":"54","author":"Daniel-Moreno","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.retram.2025.103545_bib0053","article-title":"CRISPR medicine for blood disorders: Progress and challenges in delivery","volume":"4","author":"Mohammadian Gol","year":"2022","journal-title":"Front Genome Ed"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0054","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12098-013-1159-8","article-title":"Common hematological disorders in children","volume":"81","author":"Bansal","year":"2014","journal-title":"Indian J Pediatr"},{"issue":"7","key":"10.1016\/j.retram.2025.103545_bib0055","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41587-020-0565-5","article-title":"The delivery challenge: fulfilling the promise of therapeutic genome editing","volume":"38","author":"van Haasteren","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.retram.2025.103545_bib0056","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1002\/pdi3.16","article-title":"Gene therapy for pediatric genetic kidney diseases","author":"Lu","year":"2023","journal-title":"Pediatric Discovery"},{"issue":"10","key":"10.1016\/j.retram.2025.103545_bib0057","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA Delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.retram.2025.103545_bib0058","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.2147\/IJN.S424723","article-title":"Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T Cells","volume":"18","author":"Prazeres","year":"2023","journal-title":"Int J Nanomedicine"},{"issue":"12","key":"10.1016\/j.retram.2025.103545_bib0059","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202451008","article-title":"Lipid nanoparticle-mediated RNA delivery for immune cell modulation","volume":"54","author":"Kim","year":"2024","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.retram.2025.103545_bib0060","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.retram.2025.103545_bib0061","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jconrel.2022.05.020","article-title":"Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells","volume":"347","author":"Patel","year":"2022","journal-title":"J. Controlled Release: Official J Controll Release Society"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0062","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","article-title":"Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells","volume":"22","author":"Billingsley","year":"2022","journal-title":"Nano Lett"},{"key":"10.1016\/j.retram.2025.103545_bib0063","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","article-title":"Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo","volume":"350","author":"Zhou","year":"2022","journal-title":"J. Controll. Rel.: Official J Controll Release Society"},{"issue":"6576","key":"10.1016\/j.retram.2025.103545_bib0064","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science (New York, NY)"},{"issue":"30","key":"10.1016\/j.retram.2025.103545_bib0065","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301515","article-title":"Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA CAR T cell engineering","volume":"12","author":"Hamilton","year":"2023","journal-title":"Adv Healthc Mater"},{"issue":"22","key":"10.1016\/j.retram.2025.103545_bib0066","doi-asserted-by":"crossref","first-page":"10179","DOI":"10.1021\/acs.nanolett.3c02573","article-title":"mRNA Lipid Nanoparticles for Ex Vivo Engineering of Immunosuppressive T Cells for Autoimmunity Therapies","volume":"23","author":"Thatte","year":"2023","journal-title":"Nano Lett"},{"issue":"13","key":"10.1016\/j.retram.2025.103545_bib0067","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2319856121","article-title":"IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation","volume":"121","author":"Tilsed","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.retram.2025.103545_bib0068","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jconrel.2023.08.014","article-title":"Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells","volume":"361","author":"Douka","year":"2023","journal-title":"J Controll Rel: Official J Controll Release Society"},{"issue":"17","key":"10.1016\/j.retram.2025.103545_bib0069","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713364","article-title":"CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo","volume":"24","author":"Golubovskaya","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.retram.2025.103545_bib0070","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1021\/acs.nanolett.3c00304","article-title":"In Vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles","volume":"23","author":"Shi","year":"2023","journal-title":"Nano Lett"},{"issue":"6656","key":"10.1016\/j.retram.2025.103545_bib0071","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science (New York, NY)"},{"issue":"9","key":"10.1016\/j.retram.2025.103545_bib0072","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","article-title":"Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells","volume":"19","author":"Lian","year":"2024","journal-title":"Nat Nanotechnol"},{"issue":"9","key":"10.1016\/j.retram.2025.103545_bib0073","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.2022019333","article-title":"Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells","volume":"142","author":"Vavassori","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.retram.2025.103545_bib0074","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1358\/dot.2017.53.11.2725754","article-title":"an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia","volume":"53","author":"Liu","year":"2017","journal-title":"Drugs of today (Barcelona, Spain"},{"issue":"16","key":"10.1016\/j.retram.2025.103545_bib0075","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New England J Med"},{"key":"10.1016\/j.retram.2025.103545_bib0076","first-page":"119","article-title":"CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges","author":"Rendo","year":"2022","journal-title":"Blood and lymphatic cancer: targets and therapy"},{"issue":"10-11","key":"10.1016\/j.retram.2025.103545_bib0077","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41417-019-0157-z","article-title":"Autologous CAR T-cell therapies supply chain: challenges and opportunities?","volume":"27","author":"Papathanasiou","year":"2020","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"10.1016\/j.retram.2025.103545_bib0078","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T Cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.retram.2025.103545_bib0079","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/mt.2009.41","article-title":"Biological gene delivery vehicles: beyond viral vectors","volume":"17","author":"Seow","year":"2009","journal-title":"Molec Therapy: J Am Society of Gene Therapy"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41571-020-00441-5","article-title":"COVID-19 in patients with cancer: managing a pandemic within a pandemic","volume":"18","author":"Horn","year":"2021","journal-title":"Nature Rev Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.retram.2025.103545_bib0081","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jha2.356","article-title":"CAR T cell therapy in solid tumors: a review of current clinical trials","volume":"3","author":"Patel","year":"2022","journal-title":"EJHaem"},{"issue":"6","key":"10.1016\/j.retram.2025.103545_bib0082","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.matt.2020.09.020","article-title":"Nanomaterials for therapeutic RNA delivery","volume":"3","author":"Han","year":"2020","journal-title":"Matter"},{"issue":"5","key":"10.1016\/j.retram.2025.103545_bib0083","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nature Rev Immunol"},{"issue":"7853","key":"10.1016\/j.retram.2025.103545_bib0084","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.retram.2025.103545_bib0085","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.2147\/IJN.S424723","article-title":"Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells","volume":"18","author":"Prazeres","year":"2023","journal-title":"Int J Nanomedicine"},{"issue":"26","key":"10.1016\/j.retram.2025.103545_bib0086","doi-asserted-by":"crossref","first-page":"E5859","DOI":"10.1073\/pnas.1805358115","article-title":"Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters","volume":"115","author":"McKinlay","year":"2018","journal-title":"Proceed National Acad Sci"},{"issue":"3","key":"10.1016\/j.retram.2025.103545_bib0087","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett"},{"issue":"11","key":"10.1016\/j.retram.2025.103545_bib0088","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett"},{"issue":"3","key":"10.1016\/j.retram.2025.103545_bib0089","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett"},{"issue":"2","key":"10.1016\/j.retram.2025.103545_bib0090","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acsbiomaterials.1c01532","article-title":"In vitro engineering chimeric antigen receptor macrophages and T cells by lipid nanoparticle-mediated mRNA delivery","volume":"8","author":"Ye","year":"2022","journal-title":"ACS Biomater Sci Eng"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0091","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.retram.2025.103545_bib0092","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.3390\/cancers12123542","article-title":"The tumor microenvironment\u2014a metabolic obstacle to NK cells\u2019 activity","volume":"12","author":"Domagala","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2025.103545_bib0093","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jconrel.2023.08.014","article-title":"Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells","volume":"361","author":"Douka","year":"2023","journal-title":"J Controll Release"},{"issue":"10","key":"10.1016\/j.retram.2025.103545_bib0094","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","article-title":"Phase 1 clinical trial of adoptive immunotherapy using \"off-the-shelf\" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia","volume":"19","author":"Boyiadzis","year":"2017","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.retram.2025.103545_bib0095","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.retram.2025.103545_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122810","article-title":"Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles","volume":"636","author":"Nakamura","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.retram.2025.103545_bib0097","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2016.01.042","article-title":"A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells","volume":"225","author":"Warashina","year":"2016","journal-title":"Journal of controlled release"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0098","doi-asserted-by":"crossref","DOI":"10.1038\/srep37849","article-title":"Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines","volume":"6","author":"Nakamura","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.retram.2025.103545_bib0099","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/acs.molpharmaceut.7b01166","article-title":"Reducing the cytotoxicity of lipid nanoparticles associated with a fusogenic cationic lipid in a natural killer cell line by introducing a polycation-based siRNA core","volume":"15","author":"Nakamura","year":"2018","journal-title":"Mol Pharm"},{"issue":"17","key":"10.1016\/j.retram.2025.103545_bib0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713364","article-title":"CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo","volume":"24","author":"Golubovskaya","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.retram.2025.103545_bib0101","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065862","article-title":"Hematopoietic stem cells and the immune system in development and aging","volume":"24","author":"Shevyrev","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.retram.2025.103545_bib0102","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/1078-0432.CCR-07-5134","article-title":"Regulation of hematopoietic stem cells by the steel factor\/KIT signaling pathway","volume":"14","author":"Kent","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6656","key":"10.1016\/j.retram.2025.103545_bib0103","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.retram.2025.103545_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122685","article-title":"Gene therapy in pediatrics - Clinical studies and approved drugs (as of 2023)","volume":"348","author":"Mohammadian Gol","year":"2024","journal-title":"Life Sci"},{"issue":"8","key":"10.1016\/j.retram.2025.103545_bib0105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nature Rev Genetics"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0106","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","article-title":"Immunogenicity of Cas9 protein","volume":"109","author":"Mehta","year":"2020","journal-title":"J Pharm Sci"},{"issue":"503","key":"10.1016\/j.retram.2025.103545_bib0107","doi-asserted-by":"crossref","first-page":"eaaw3768","DOI":"10.1126\/scitranslmed.aaw3768","article-title":"Therapeutically relevant engraftment of a CRISPR-Cas9\u2013edited HSC-enriched population with HbF reactivation in nonhuman primates","volume":"11","author":"Humbert","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.retram.2025.103545_bib0108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.omtn.2018.04.017","article-title":"Priming human repopulating hematopoietic stem and progenitor cells for Cas9\/sgRNA gene targeting","volume":"12","author":"Charlesworth","year":"2018","journal-title":"Molec Therapy-Nucleic Acids"},{"issue":"6","key":"10.1016\/j.retram.2025.103545_bib0109","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","article-title":"Delivery aspects of CRISPR\/Cas for in vivo genome editing","volume":"52","author":"Wilbie","year":"2019","journal-title":"Acc Chem Res"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40164-020-00161-7","article-title":"Clinical implications of recurrent gene mutations in acute myeloid leukemia","volume":"9","author":"Yu","year":"2020","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"10.1016\/j.retram.2025.103545_bib0111","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/ncb1608","article-title":"NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis","volume":"9","author":"Wang","year":"2007","journal-title":"Nat Cell Biol"},{"issue":"9","key":"10.1016\/j.retram.2025.103545_bib0112","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3324\/haematol.2013.100917","article-title":"Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction","volume":"99","author":"Thanasopoulou","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.retram.2025.103545_bib0113","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.3390\/cancers12102766","article-title":"Targeted inhibition of the NUP98-NSD1 fusion oncogene in acute myeloid leukemia","volume":"12","author":"Mohanty","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2025.103545_bib0114","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00277-019-03713-y","article-title":"Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo","volume":"98","author":"Jyotsana","year":"2019","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.retram.2025.103545_bib0115","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol Pharm"},{"issue":"21","key":"10.1016\/j.retram.2025.103545_bib0116","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg3217","article-title":"Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy","volume":"7","author":"Ho","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.retram.2025.103545_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123695","article-title":"Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines","volume":"650","author":"Yang","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.retram.2025.103545_bib0118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154-155","author":"Kozma","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.retram.2025.103545_bib0119","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2022.12.039","article-title":"Anti-PEG antibodies before and after a first dose of Comirnaty\u00ae (mRNA-LNP-based SARS-CoV-2 vaccine)","volume":"354","author":"Bavli","year":"2023","journal-title":"J Controll Rel"},{"issue":"8","key":"10.1016\/j.retram.2025.103545_bib0120","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA Vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.retram.2025.103545_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124695","article-title":"Replacing poly(ethylene glycol) with RAFT lipopolymers in mRNA lipid nanoparticle systems for effective gene delivery","volume":"665","author":"Hassanel","year":"2024","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.retram.2025.103545_bib0122","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1021\/acs.biomac.4c00651","article-title":"Tailored Monoacyl Poly(2-oxazoline)- and Poly(2-oxazine)-Lipids as PEG-Lipid Alternatives for Stabilization and Delivery of mRNA-Lipid Nanoparticles","volume":"25","author":"He","year":"2024","journal-title":"Biomacromolecules"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0123","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J Controll Rel"},{"key":"10.1016\/j.retram.2025.103545_bib0124","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jconrel.2020.12.047","article-title":"Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines","volume":"330","author":"Zhang","year":"2021","journal-title":"J Controll Release"},{"issue":"3","key":"10.1016\/j.retram.2025.103545_bib0125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J Controll Release"},{"key":"10.1016\/j.retram.2025.103545_bib0126","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpb.2020.04.026","article-title":"Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice","volume":"152","author":"Elsadek","year":"2020","journal-title":"Eur J Pharmaceut Biopharmaceut"},{"key":"10.1016\/j.retram.2025.103545_bib0127","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2020.04.011","article-title":"Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon","volume":"323","author":"El Sayed","year":"2020","journal-title":"J Controll Release"},{"key":"10.1016\/j.retram.2025.103545_bib0128","first-page":"1","article-title":"Clinical relevance of pre-existing and treatment-induced anti-poly (ethylene glycol) antibodies","author":"Haddad","year":"2021","journal-title":"Regen Eng Transl Med"},{"issue":"2","key":"10.1016\/j.retram.2025.103545_bib0129","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.imbio.2011.07.027","article-title":"Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth","volume":"217","author":"McGreal","year":"2012","journal-title":"Immunobiology"},{"issue":"6","key":"10.1016\/j.retram.2025.103545_bib0130","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater Au"},{"key":"10.1016\/j.retram.2025.103545_bib0131","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","article-title":"Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery","volume":"344","author":"Maeki","year":"2022","journal-title":"J Controll Release: Official J Controll Release Society"},{"issue":"2","key":"10.1016\/j.retram.2025.103545_bib0132","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1039\/D3LC00520H","article-title":"3D-printed microfluidic device for high-throughput production of lipid nanoparticles incorporating SARS-CoV-2 spike protein mRNA","volume":"24","author":"Lin","year":"2024","journal-title":"Lab Chip"},{"issue":"13","key":"10.1016\/j.retram.2025.103545_bib0133","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1021\/acs.nanolett.1c01353","article-title":"Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device","volume":"21","author":"Shepherd","year":"2021","journal-title":"Nano Lett"},{"key":"10.1016\/j.retram.2025.103545_bib0134","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120826","article-title":"Microfluidic formulation of nanoparticles for biomedical applications","volume":"274","author":"Shepherd","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.retram.2025.103545_bib0135","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Molecular Therapy Nucleic Acids"},{"issue":"11","key":"10.1016\/j.retram.2025.103545_bib0136","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/pharmaceutics12111095","article-title":"Manufacturing considerations for the development of lipid nanoparticles using microfluidics","volume":"12","author":"Roces","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.retram.2025.103545_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0138","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/s41467-021-26926-0","article-title":"A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems","volume":"12","author":"Packer","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2025.103545_bib0139","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.11.022","article-title":"Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines","volume":"353","author":"Kim","year":"2023","journal-title":"J Controll Release"},{"issue":"3","key":"10.1016\/j.retram.2025.103545_bib0140","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jconrel.2009.10.024","article-title":"An overview of liposome lyophilization and its future potential","volume":"142","author":"Chen","year":"2010","journal-title":"J Controll Release"},{"issue":"3","key":"10.1016\/j.retram.2025.103545_bib0141","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ejhg.2013.145","article-title":"An efficient method for long-term room temperature storage of RNA","volume":"22","author":"Fabre","year":"2014","journal-title":"Eur J Human Genetics"},{"key":"10.1016\/j.retram.2025.103545_bib0142","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.addr.2019.03.003","article-title":"Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments","volume":"151","author":"Wang","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.retram.2025.103545_bib0143","first-page":"358","article-title":"Long-term storage of lipid-like nanoparticles for mRNA delivery","volume":"5","author":"Zhao","year":"2020","journal-title":"Bioact Mater"},{"issue":"1","key":"10.1016\/j.retram.2025.103545_bib0144","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41421-022-00517-9","article-title":"Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2","volume":"9","author":"Ai","year":"2023","journal-title":"Cell Discov"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318625000546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:14:16Z","timestamp":1765584856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318625000546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":144,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2452318625000546"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2025.103545","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revolutionizing pediatric gene and cell therapy: The hope for lipid-based nanoparticles in blood disorders","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2025.103545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103545"}}